Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022
21 mars 2022 08h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, March 21, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
10 mars 2022 08h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, March 10, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08 févr. 2022 17h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
14 déc. 2021 16h30 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Appoints Sailaja Puttagunta, MD as Chief Medical Officer
13 déc. 2021 08h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next...
Iterum Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
12 nov. 2021 07h00 HE
|
Iterum Therapeutics plc
--Type B meeting with FDA requested to affirm design for additional Phase 3 trial needed for resubmission of NDA for Oral Sulopenem-- --Cash Runway into 2024-- --Iterum to host conference call...
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on November 12, 2021
05 nov. 2021 07h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Provides Update from FDA Type A Meeting Regarding Oral Sulopenem
28 sept. 2021 08h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics to Present Data at IDWeek 2021
28 sept. 2021 07h30 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
08 sept. 2021 08h55 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...